de Boer, I. H. et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305, 2532–2539 (2011).
de Boer, I. H., Group DER. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37, 24–30 (2014).
Afkarian, M. et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA 316, 602–610 (2016).
Koye, D. N., Magliano, D. J., Nelson, R. G. & Pavkov, M. E. The global epidemiology of diabetes and kidney disease. Adv. Chronic Kidney Dis. 25, 121–132 (2018).
Agrawal, L. et al. Intensive glycemic control improves long-term renal outcomes in type 2 diabetes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 42, e181–e182 (2019).
Agrawal, L. et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care 34, 2090–2094 (2011).
Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456–1462 (1993).
Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).
Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861–869 (2001).
Fried, L. F. et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 369, 1892–1903 (2013).
Parving, H. H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204–2213 (2012).
Mann, J. F. et al. Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol. 21, 527–535 (2010).
de Zeeuw, D. et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492–2503 (2013).
Packham, D. K. et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 23, 123–130 (2012).
The E-KCG. et al. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 388, 117–127 (2023).
Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).
Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).
Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020).
Heerspink, H. J. L. et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393, 1937–1947 (2019).
International Diabetes Federation. IDF Diabetes Atlas, 10th edn. https://www.diabetesatlas.org (2021).
Menke, A., Casagrande, S., Geiss, L. & Cowie, C. C. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 314, 1021–1029 (2015).
Jager, K. J. et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 96, 1048–1050 (2019).
Toppe, C. et al. Decreasing cumulative incidence of end-stage renal disease in young patients with type 1 diabetes in Sweden: a 38-year prospective nationwide study. Diabetes Care 42, 27–31 (2019).
Gregg, E. W., Hora, I. & Benoit, S. R. Resurgence in diabetes-related complications. JAMA 321, 1867–1868 (2019).
Narres, M. et al. Incidence and relative risk of renal replacement therapy in people with and without diabetes between 2002 and 2016 in a German region. Diabetologia 63, 648–658 (2020).
Koye, D. N. et al. Trends in incidence of ESKD in people with type 1 and type 2 diabetes in Australia, 2002–2013. Am. J. Kidney Dis. 73, 300–308 (2019).
Wu, H. et al. Trends in kidney failure and kidney replacement therapy in people with diabetes in Hong Kong, 2002–2015: a retrospective cohort study. Lancet Reg. Health West Pac. 11, 100165 (2021).
Harding, J. L., Pavkov, M. E., Magliano, D. J., Shaw, J. E. & Gregg, E. W. Global trends in diabetes complications: a review of current evidence. Diabetologia 62, 3–16 (2019).
Afkarian, M. et al. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 24, 302–308 (2013).
Fox, C. S. et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 380, 1662–1673 (2012).
Wen, C. P. et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int. 92, 388–396 (2017).
Fioretto, P. & Mauer, M. Histopathology of diabetic nephropathy. Semin. Nephrol. 27, 195–207 (2007).
Fiorentino, M. et al. Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies. Nephrol. Dial. Transpl. 32, 97–110 (2017).
Fioretto, P. et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39, 1569–1576 (1996).
Jin, Q. et al. Nonalbuminuric diabetic kidney disease and risk of all-cause mortality and cardiovascular and kidney outcomes in type 2 diabetes: findings from the Hong Kong Diabetes Biobank. Am. J. Kidney Dis. 80, 196–206 e1 (2022).
Nosadini, R. et al. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 49, 476–484 (2000).
Fioretto, P., Steffes, M. W., Sutherland, D. E., Goetz, F. C. & Mauer, M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med. 339, 69–75 (1998).
Scholtes, R. A. et al. Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors. Nephrology 26, 377–390 (2021).
Scholtes, R. A. et al. Kidney hemodynamic effects of angiotensin receptor blockade, sodium-glucose cotransporter-2 inhibition alone, and their combination: a crossover randomized trial in people with type 2 diabetes. Circulation 146, 1895–1897 (2022).
Romero, C. A., Orias, M. & Weir, M. R. Novel RAAS agonists and antagonists: clinical applications and controversies. Nat. Rev. Endocrinol. 11, 242–252 (2015).
Rayego-Mateos, S. et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int. 103, 282–296 (2023).
Ma, T. K., Kam, K. K., Yan, B. P. & Lam, Y. Y. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br. J. Pharmacol. 160, 1273–1292 (2010).
van Bommel, E. J. et al. SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome. Clin. J. Am. Soc. Nephrol. 12, 700–710 (2017).
Persson, F. et al. Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial. Diabetes Care 44, 1894–1897 (2021).
van Bommel, E. J. M. et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int. 97, 202–212 (2020).
Cherney, D. Z. et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129, 587–597 (2014).
Heerspink, H. J., Perkins, B. A., Fitchett, D. H., Husain, M. & Cherney, D. Z. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134, 752–772 (2016).
Nuffield Department of Population Health Renal Studies G, Consortium SiM-AC-RT. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400, 1788–1801 (2022).
Neuen, B. L. et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation 145, 1460–1470 (2022).
Bolignano, D., Palmer, S. C., Navaneethan, S. D. & Strippoli, G. F. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst. Rev. 10, CD007004 (2014).
Alexandrou, M. E. et al. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. J. Hypertens. 37, 2307–2324 (2019).
Kolkhof, P. et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J. Cardiovasc. Pharmacol. 64, 69–78 (2014).
Gerisch, M. et al. Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro. Drug Metab. Dispos. 46, 1546–1555 (2018).
Agarwal, R. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur. Heart J. 43, 474–484 (2022).
Agarwal, R. et al. Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. J. Am. Soc. Nephrol. 33, 225–237 (2022).
Ito, S. et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin. J. Am. Soc. Nephrol. 15, 1715–1727 (2020).
Barton, M. & Yanagisawa, M. Endothelin: 30 years from discovery to therapy. Hypertension 74, 1232–1265 (2019).
Chung, E. Y. M., Badve, S. V., Heerspink, H. J. L. & Wong, M. G. Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond? Nephrology 28, 97–108 (2023).
Weber, M. A. et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374, 1423–1431 (2009).
Muskiet, M. H. A. et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat. Rev. Nephrol. 13, 605–628 (2017).
Drucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 27, 740–756 (2018).
Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653–662 (2021).
Shaman, A. M. et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 145, 575–585 (2022).
Tuttle, K. R. et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int. 103, 772–781 (2023).
Mann, J. F. E. et al. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377, 839–848 (2017).
Mann, J. F. E. et al. Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis. Diabetes Obes. Metab. 23, 2058–2066 (2021).
Muskiet, M. H. A. et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 6, 859–869 (2018).
Alicic, R. Z., Cox, E. J., Neumiller, J. J. & Tuttle, K. R. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat. Rev. Nephrol. 17, 227–244 (2021).
Pichler, R., Afkarian, M., Dieter, B. P. & Tuttle, K. R. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. Am. J. Physiol. Renal Physiol. 312, F716–F731 (2017).
Ronn, J., Jensen, E. P., Wewer Albrechtsen, N. J., Holst, J. J. & Sorensen, C. M. Glucagon-like peptide-1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP-1 receptors. Physiol. Rep. 5, e13503 (2017).
Gutzwiller, J. P. et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 89, 3055–3061 (2004).
Muskiet, M. H. et al. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. Diabetes Obes. Metab. 18, 178–185 (2016).
Tonneijck, L. et al. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus. Am. J. Physiol. Renal Physiol. 316, F231–F240 (2019).
Rossing, P. et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol. Dial. Transpl. 38, 2041–2051 (2023).
A research study to find out how semaglutide works in the kidneys compared to placebo, in people with type 2 diabetes and chronic kidney disease (the REMODEL trial) (REMODEL). ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04865770 (2024).
Kalantar-Zadeh, K. & Fouque, D. Nutritional management of chronic kidney disease. N. Engl. J. Med. 377, 1765–1776 (2017).
Suckling R. J., He F. J., Macgregor G. A. Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst. Rev. 2010:CD006763.
de Boer, I. H. et al. Executive summary of the 2020 KDIGO diabetes management in CKD guideline: evidence-based advances in monitoring and treatment. Kidney Int. 98, 839–848 (2020).
Kwakernaak, A. J. et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. Lancet Diabetes Endocrinol. 2, 385–395 (2014).
Dietary sodium intake effects on ertugliflozin-induced changes in GFR, renal oxygenation and systemic hemodynamics: the DESIGN study (DESIGN). ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05727579 (2023).
Yan, B., Su, X., Xu, B., Qiao, X. & Wang, L. Effect of diet protein restriction on progression of chronic kidney disease: a systematic review and meta-analysis. PLoS One 13, e0206134 (2018).
Bosch, J. P. et al. Renal functional reserve in humans. Effect of protein intake on glomerular filtration rate. Am. J. Med. 75, 943–950 (1983).
Look ARG. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2, 801–809 (2014).
Shulman, A. et al. Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study. Int. J. Obes. 42, 964–973 (2018).
O’Hare, A. M., Tawney, K., Bacchetti, P. & Johansen, K. L. Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2. Am. J. Kidney Dis. 41, 447–454 (2003).
Wilkinson, T. J., McAdams-DeMarco, M., Bennett, P. N. & Wilund, K., Global Renal Exercise N. Advances in exercise therapy in predialysis chronic kidney disease, hemodialysis, peritoneal dialysis, and kidney transplantation. Curr. Opin. Nephrol. Hypertens. 29, 471–479 (2020).
Zelle, D. M. et al. Physical inactivity: a risk factor and target for intervention in renal care. Nat. Rev. Nephrol. 13, 318 (2017).
Efficacy of a high-intensity physical activity program on renal function in high risk patients with type 2 diabetes (ACTIDIANE). ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03184662 (2021).
Liu, J. et al. Multi-scalar data integration links glomerular angiopoietin-tie signaling pathway activation with progression of diabetic kidney disease. Diabetes 71, 2664–2676 (2022).
Stefansson, V. T. N. et al. Molecular programs associated with glomerular hyperfiltration in early diabetic kidney disease. Kidney Int. 102, 1345–1358 (2022).
Nair, V. et al. A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome. Kidney Int. 93, 439–449 (2018).
Sas, K. M. et al. Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications. JCI Insight 1, e86976 (2016).
Wilson, P. C. et al. The single-cell transcriptomic landscape of early human diabetic nephropathy. Proc. Natl Acad. Sci. USA 116, 19619–19625 (2019).
Wu, H. et al. Mapping the single-cell transcriptomic response of murine diabetic kidney disease to therapies. Cell Metab. 34, 1064–78 e6 (2022).
Hodgin, J. B. et al. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes 62, 299–308 (2013).
Brosius, F. C. III et al. Mouse models of diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2503–2512 (2009).
Kolkhof, P. et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52, 642–652 (2021).
Vergara, A. et al. Enhanced cardiorenal protective effects of combining SGLT2 inhibition, endothelin receptor antagonism and RAS blockade in type 2 diabetic mice. Int. J. Mol. Sci. 23, 12823 (2022).
Seidu, S., Kunutsor, S. K., Topsever, P. & Khunti, K. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrinol. Diabetes Metab. 5, e00303 (2022).
Lytvyn, Y. et al. Renal and vascular effects of combined SGLT2 and angiotensin-converting enzyme inhibition. Circulation 146, 450–462 (2022).
Phadke, G. et al. Osmotic nephrosis and acute kidney injury associated with SGLT2 inhibitor use: a case report. Am. J. Kidney Dis. 76, 144–147 (2020).
Promoting effective renoprotection in cardiac surgery patients by inhibition of SGLT-2 (MERCURI-2). ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05590143 (2023).
Hesp, A. C. et al. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors? Kidney Int. 98, 579–589 (2020).
Puglisi, S. et al. Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system. Front. Endocrinol. 12, 738848 (2021).
Jabbour, S. A. et al. Efficacy and safety over 2 years of exenatide plus dapagliflozin in the DURATION-8 study: a multicenter, double-blind, phase 3, randomized controlled trial. Diabetes Care 43, 2528–2536 (2020).
Gerstein, H. C. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N. Engl. J. Med. 385, 896–907 (2021).
Lam, C. S. P. et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation 145, 565–574 (2022).
van der Aart-van der Beek, A. B. et al. Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: a randomized cross-over clinical study. Diabetes Obes. Metab. 25, 1758–1768 (2023).
van Ruiten, C. C. et al. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial. Diabetes Obes. Metab. 23, 1851–1858 (2021).
Gullaksen, S. et al. Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial. Diabetologia 66, 813–825 (2023).
Wright, A. K. et al. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care 45, 909–918 (2022).
Pitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385, 2252–2263 (2021).
Rossing, P. et al. Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care 45, 2991–2998 (2022).
Rossing, P. et al. Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use. Diabetes Obes. Metab. 25, 407–416 (2023).
Provenzano, M. et al. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial. J. Am. Soc. Nephrol. 33, 1569–1580 (2022).
A study to learn how well the treatment combination of finerenone and empagliflozin works and how safe it is compared to each treatment alone in adult participants with long-term kidney disease (chronic kidney disease) and type 2 diabetes (CONFIDENCE). ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05254002 (2024).
Heerspink, H. J. L., Kohan DE & de Zeeuw, D. New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. Kidney Int. 99, 346–349 (2021).
Zibotentan and dapagliflozin for the treatment of CKD (ZENITH-CKD Trial) (ZENITH-CKD). ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04724837 (2023).
Zibotentan and dapagliflozin in patients with type 2 diabetes and elevated albuminuria (ZODIAC). ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05570305 (2023).
Rosenstock, J. et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care 41, 2560–2569 (2018).
Phillip, M. et al. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies. Diabetes Obes. Metab. 23, 549–560 (2021).
Sands, A. T. et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 38, 1181–1188 (2015).
Garg, S. K. et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N. Engl. J. Med. 377, 2337–2348 (2017).
Buse, J. B. et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. Diabetes Care 41, 1970–1980 (2018).
van Raalte, D. H. et al. The impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes. Diabetes Care 42, 1921–1929 (2019).
Cherney, D. Z. I. et al. Kidney effects of empagliflozin in people with type 1 diabetes. Clin. J. Am. Soc. Nephrol. 16, 1715–1719 (2021).
Stougaard, E. B., Rossing, P., Cherney, D., Vistisen, D. & Persson, F. Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines. J. Diabetes Complications 36, 108257 (2022).
Wheeler, D. C. et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 9, 22–31 (2021).
Semaglutide effects on heart disease and stroke in patients with overweight or obesity (SELECT). ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03574597 (2024).
Semaglutide and albuminuria reduction trial in obese individuals without diabetes (SMART). ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04889183 (2023).
A trial to learn how well finerenone works and how safe it is in adult participants with non-diabetic chronic kidney disease (FIND-CKD). ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05047263 (2024).
Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45, 2753–2786 (2022).
Kidney Disease: Improving Global Outcomes Diabetes Work G. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 102, S1–S127 (2022).
Joseph, J. J. et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation 145, e722–e759 (2022).
Blonde, L. et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan — 2022 update. Endocr. Pract. 28, 923–1049 (2022).
American Diabetes Association Professional Practice C. 11. Chronic kidney disease and risk management: standards of medical care in diabetes — 2022. Diabetes Care 45, S175–S184 (2022).
de Boer, I. H. et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 45, 3075–3090 (2022).
van der Sande, N. G. et al. Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy. Diabetes Obes. Metab. 18, 1120–1127 (2016).
Tye, S. C. et al. Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure. Cardiovasc. Diabetol. 21, 194 (2022).
Chertow, G. M. et al. Effects of dapagliflozin in chronic kidney disease, with and without other cardiovascular medications: DAPA-CKD trial. J. Am. Heart Assoc. 12, e028739 (2023).
Curovic, V. R. et al. Optimization of albuminuria-lowering treatment in diabetes by crossover rotation to four different drug classes: a randomized crossover trial. Diabetes Care 46, 593–601 (2023).
A research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW). ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03819153 (2024).
Heerspink, H. J. L. et al. Design of FLAIR: a phase 2b study of the 5-lipoxygenase activating protein inhibitor AZD5718 in patients with proteinuric CKD. Kidney Int. Rep. 6, 2803–2810 (2021).
A phase 2b diabetic kidney disease study. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04170543 (2023).
Frimodt-Moller, M., Persson, F. & Rossing, P. Mitigating risk of aldosterone in diabetic kidney disease. Curr. Opin. Nephrol. Hypertens. 29, 145–151 (2020).
Stasch, J. P., Schlossmann, J. & Hocher, B. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Curr. Opin. Pharmacol. 21, 95–104 (2015).
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B. & Thomson, A. W. Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. Nat. Rev. Nephrol. 12, 587–609 (2016).
Heerspink, H. J. L. et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 10, 774–785 (2022).
Hammoud, R. & Drucker, D. J. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat. Rev. Endocrinol. 19, 201–216 (2023).
A study of tirzepatide (LY3298176) in participants with overweight or obesity and chronic kidney disease with or without type 2 diabetes (TREASURE-CKD). ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05536804 (2024).
Ruiz-Andres, O. et al. Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms. Am. J. Physiol. Renal Physiol. 311, F1329–F1340 (2016).
Mora-Fernandez, C. et al. Sodium-glucose co-transporter-2 inhibitors increase Klotho in patients with diabetic kidney disease: a clinical and experimental study. Biomed. Pharmacother. 154, 113677 (2022).
- The Renal Warrior Project. Join Now
- Source: https://www.nature.com/articles/s41581-024-00827-z